Kimberly-Clark: Kenvue Deal Comes With Considerable Risks, but Shares Look Cheap

Key Morningstar Metrics for Kimberly-Clark

• Fair Value Estimate: $133.00
• Morningstar Rating: ★★★★
• Morningstar Economic Moat Rating: Narrow
• Morningstar Uncertainty Rating: High

Kimberly-Clark KMB will acquire Kenvue KVUE for $48.7 billion, with Kenvue shareholders receiving $3.50 per share in cash and 0.14625 Kimberly shares upon the transaction’s close in second-half 2026. The deal values Kenvue at 14 times adjusted EBITDA. Kimberly shares sank around 12% on the news on Nov. 3.

Why it matters: This deal marks a significant shift, as Kimberly has been slimming down by exiting its Brazilian tissue business, personal protective equipment, and North American private label while preparing to spin off its international tissue business into a joint venture next year.

• Despite bolstering the scale of the combined firm, we foresee sizable integration risk. Kenvue has faced challenges since its split from Johnson & Johnson in 2023, as it has been slow to embed key tenets for competing in the intensely competitive consumer packaged goods space.
• Beyond parting ways with the unperforming pieces of Kenvue’s portfolio (with management citing the potential for a 30% reduction of stock-keeping units), we also expect areas such as harnessing its distribution reach and more effectively spending behind its brands to be of primary focus.

The bottom line: We lower our fair value estimate for narrow-moat Kimberly-Clark to $133 per share from $140 and our Capital Allocation Rating to Standard from Exemplary. We raise our Uncertainty Rating to High from Medium. Shares are undervalued, reflecting concerns around integration risk.

• It targets $1.9 billion in cost synergies (30% from sales, marketing, and trade spending, 30% from cost of goods sold, and 40% from general and administrative). This equates to about 15% of Kenvue’s cost of goods sold and operating expenses, which seems high to us.

Between the lines: Although we don’t see any anticompetitive concerns that would thwart the tie-up, we’re aware of Kenvue’s lingering litigation risk around talc and Tylenol, each of which could outlast its tenure as an independent organization.